Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$9.35 USD
+0.95 (11.31%)
Updated Sep 20, 2024 04:00 PM ET
Pre-Market: $9.69 +0.34 (3.64%) 9:14 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 21 - 40 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Galmed Takes Its First Step in Developing Combination Therapy With Aramchol; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
2Q20 Recap: Phase 3 ARMOR Complete Enrollment by 4Q21; New Anti-Inflammatory Program Unveiled; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare- Three Must Dial-In Calls Next Week:
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Three Must Dial-In Calls Next Week: NASH, Omega-3s, and COVID-19 - MS
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
1Q20 Recap: Surprise Announcement Addresses Long-Standing Overhang of Limited Patent Protection
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
1Q20 - Salt Version of Aramchol Potentially Means an Upgrade in ARMOR
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
NASH: Impact of Semaglutide GLP-1 NASH Data on NASH Stocks
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Do Not Miss Our GLP-1 Call with Dr. Juan Frias Today at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Do Not Miss Part 1 on Monday of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 19 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
4Q19 Recap: Contingency Plans for COVID-19 to Keep ARMOR Study on Track; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E